Literature DB >> 6678865

Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin.

M Ogawa, H Miyamoto, J Inigaki, N Horikoshi, K Ezaki, K Inoue, K Ikeda, N Usui, H Nakada.   

Abstract

The phase I study of a new anthracycline, 4'-o-tetrahydropyranyl adriamycin, was performed. A dose-limiting factor was leukopenia while thrombocytopenia was less frequent and a maximum tolerated dose was determined as 54 mg/m2. Mild gastrointestinal toxicities including anorexia, nausea and vomiting occurred in about half of the patients, while very minimal alopecia was seen in only one patient. A recommended dose for phase II study was established: 40 mg/m2 at 3-week intervals.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6678865     DOI： 10.1007/bf00172076

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  4 in total

Review 1.  Adriamycin. A new anticancer drug with significant clinical activity.

Authors:  R H Blum; S K Carter
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

2.  Tetrahydropyranyl derivatives of daunomycin and adriamycin.

Authors:  H Umezawa; Y Takahashi; M Kinoshita; H Naganawa; T Masuda; M Ishizuka; K Tatsuta; T Takeuchi
Journal:  J Antibiot (Tokyo)       Date:  1979-10       Impact factor: 2.649

3.  4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

4.  Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.

Authors:  D Dantchev; M Paintrand; M Hayat; C Bourut; G Mathé
Journal:  J Antibiot (Tokyo)       Date:  1979-10       Impact factor: 2.649
  4 in total
  6 in total

1.  (2"-R)-4'-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies.

Authors:  T Takagi; M Oguro
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  A phase II study of (2"R)-4'-0-tetrahydropyranyladriamycin (THP) in hematological malignancies.

Authors:  K Yamada; S Shirakawa; R Ohno; H Yamada; Y Hirota; K Ohara; K Yamagata; M Kobayashi; M Hirano; Y Ikeda
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

3.  Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.

Authors:  B T Hill; L Y Dennis; X T Li; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin.

Authors:  R Ohno; K Kimura; I Amaki; M Hirano; A Hoshino; Y Ikeda; I Kimura; M Kobayashi; K Konno; H Majima
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin).

Authors:  M N Raber; R A Newman; K Lu; S Legha; C Gorski; R S Benjamin; I H Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.

Authors:  J Robert; A Monnier; N Poutignat; P Hérait
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.